Financial Ratios Chongqing Zhifei Biological Products Co., Ltd.
Stocks
300122
CNE100000V20
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.59 CNY | +4.05% |
|
-2.25% | -33.28% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 32.93 | 15.98 | 13.04 | 2.92 | -25.87 | |||||
Return on Total Capital | 50.36 | 24.3 | 18.92 | 3.76 | -29.62 | |||||
Return On Equity % | 78.81 | 35.99 | 28.95 | 6.48 | -62.8 | |||||
Return on Common Equity | 78.81 | 35.99 | 28.95 | 6.48 | -63.06 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 48.73 | 33.31 | 26.31 | 27.23 | -144.17 | |||||
SG&A Margin | 6.97 | 6.78 | 5.96 | 11.68 | 31.26 | |||||
EBITDA Margin % | 40.11 | 23.52 | 17.98 | 10.4 | -186.22 | |||||
EBITA Margin % | 39.26 | 22.83 | 17.43 | 9.06 | -191.29 | |||||
EBIT Margin % | 38.9 | 22.73 | 17.4 | 8.97 | -191.79 | |||||
Income From Continuing Operations Margin % | 33.3 | 19.7 | 15.25 | 7.74 | -164.6 | |||||
Net Income Margin % | 33.3 | 19.7 | 15.25 | 7.74 | -164.35 | |||||
Net Avail. For Common Margin % | 33.3 | 19.7 | 15.25 | 7.74 | -164.35 | |||||
Normalized Net Income Margin | 24.27 | 14.18 | 10.82 | 5.33 | -122.04 | |||||
Levered Free Cash Flow Margin | 9.42 | -10.27 | 2.82 | -40.41 | 82.99 | |||||
Unlevered Free Cash Flow Margin | 9.53 | -10.19 | 2.92 | -40.06 | 85.3 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.35 | 1.12 | 1.2 | 0.52 | 0.22 | |||||
Fixed Assets Turnover | 10.31 | 9.28 | 10.78 | 4.97 | 1.49 | |||||
Receivables Turnover (Average Receivables) | 3.14 | 2.29 | 2.22 | 1.19 | 0.65 | |||||
Inventory Turnover (Average Inventory) | 2.91 | 3.31 | 4.59 | 1.22 | 1.61 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.09 | 2.37 | 2.35 | 2.24 | 1.53 | |||||
Quick Ratio | 1.45 | 1.76 | 1.85 | 1.03 | 1.12 | |||||
Operating Cash Flow to Current Liabilities | 0.72 | 0.15 | 0.5 | -0.24 | 0.42 | |||||
Days Sales Outstanding (Average Receivables) | 116.14 | 159.71 | 164.42 | 306.8 | 565.25 | |||||
Days Outstanding Inventory (Average Inventory) | 125.32 | 110.18 | 79.59 | 301 | 227.33 | |||||
Average Days Payable Outstanding | 113.64 | 132.48 | 104.8 | 105.48 | 278.19 | |||||
Cash Conversion Cycle (Average Days) | 127.83 | 137.4 | 139.21 | 502.32 | 514.39 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 4.63 | 8.39 | 9.63 | 40.09 | 76.29 | |||||
Total Debt / Total Capital | 4.43 | 7.74 | 8.79 | 28.61 | 43.27 | |||||
LT Debt/Equity | 1.41 | 0.98 | 1.12 | 1.18 | 18.12 | |||||
Long-Term Debt / Total Capital | 1.35 | 0.91 | 1.02 | 0.84 | 10.28 | |||||
Total Liabilities / Total Assets | 41.24 | 36.23 | 37.28 | 38.23 | 49.22 | |||||
EBIT / Interest Expense | 212.39 | 163.21 | 113.66 | 15.92 | -51.9 | |||||
EBITDA / Interest Expense | 219.06 | 169.08 | 117.62 | 18.54 | -50.35 | |||||
(EBITDA - Capex) / Interest Expense | 184.65 | 141.82 | 103.62 | 12.21 | -52.22 | |||||
Total Debt / EBITDA | 0.07 | 0.23 | 0.32 | 4.54 | -0.74 | |||||
Net Debt / EBITDA | -0.28 | -0.07 | -0.35 | 3.55 | -0.58 | |||||
Total Debt / (EBITDA - Capex) | 0.08 | 0.27 | 0.36 | 6.89 | -0.71 | |||||
Net Debt / (EBITDA - Capex) | -0.34 | -0.08 | -0.39 | 5.39 | -0.56 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 101.79 | 24.83 | 38.3 | -50.74 | -65.61 | |||||
Gross Profit, 1 Yr. Growth % | 154.28 | -14.6 | 9.22 | -49.05 | -282.34 | |||||
EBITDA, 1 Yr. Growth % | 197.56 | -26.8 | 5.68 | -71.53 | -732.75 | |||||
EBITA, 1 Yr. Growth % | 199.01 | -27.41 | 5.55 | -74.4 | -850.19 | |||||
EBIT, 1 Yr. Growth % | 197.28 | -27.06 | 5.84 | -74.61 | -861.62 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 209.23 | -26.15 | 7.04 | -74.99 | -859.87 | |||||
Net Income, 1 Yr. Growth % | 209.23 | -26.15 | 7.04 | -74.99 | -846.42 | |||||
Normalized Net Income, 1 Yr. Growth % | 206.74 | -27.04 | 5.47 | -75.74 | -903.67 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 209.23 | -26.15 | 7.04 | -74.94 | -846.89 | |||||
Accounts Receivable, 1 Yr. Growth % | 94.25 | 60.2 | 31.26 | -39.86 | -31.51 | |||||
Inventory, 1 Yr. Growth % | 116.86 | 8.6 | 12.04 | 147.25 | -77.51 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 49.04 | 31.94 | 9.1 | 4.89 | -4.63 | |||||
Total Assets, 1 Yr. Growth % | 97.48 | 26.48 | 32.18 | -0.64 | -38.16 | |||||
Tangible Book Value, 1 Yr. Growth % | 117.31 | 37.98 | 30.61 | -2.11 | -49.99 | |||||
Common Equity, 1 Yr. Growth % | 114.06 | 37.26 | 30 | -2.14 | -48.66 | |||||
Cash From Operations, 1 Yr. Growth % | 143.3 | -76.62 | 352.3 | -149.06 | -222.33 | |||||
Capital Expenditures, 1 Yr. Growth % | 133.63 | -24.79 | -21.95 | -17.97 | -48.44 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -3.09T | -236.15 | -138.01 | -804.97 | -170.58 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -17.08T | -233.37 | -139.64 | -775.92 | -173.24 | |||||
Dividend Per Share, 1 Yr. Growth % | 20.01 | -16.68 | 140.02 | -75 | - | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 70.15 | 58.71 | 31.39 | -17.46 | -58.86 | |||||
Gross Profit, 2 Yr. CAGR % | 83.56 | 47.3 | -3.42 | -25.37 | -3.71 | |||||
EBITDA, 2 Yr. CAGR % | 104 | 47.59 | -12.04 | -45.13 | 32.39 | |||||
EBITA, 2 Yr. CAGR % | 104.48 | 47.33 | -12.46 | -48.01 | 36.28 | |||||
EBIT, 2 Yr. CAGR % | 103.98 | 47.26 | -12.13 | -48.16 | 36.61 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 107.7 | 51.12 | -11.09 | -48.26 | 35.17 | |||||
Net Income, 2 Yr. CAGR % | 107.7 | 51.12 | -11.09 | -48.26 | 35.07 | |||||
Normalized Net Income, 2 Yr. CAGR % | 106.5 | 49.6 | -12.28 | -49.42 | 38.2 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 107.7 | 51.12 | -11.09 | -48.2 | 35.25 | |||||
Accounts Receivable, 2 Yr. CAGR % | 70.29 | 76.41 | 45.01 | -11.15 | -35.77 | |||||
Inventory, 2 Yr. CAGR % | 72.41 | 53.46 | 10.31 | 66.44 | -25.38 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 33.9 | 40.23 | 19.98 | 6.97 | 7.16 | |||||
Total Assets, 2 Yr. CAGR % | 65.71 | 58.04 | 29.3 | 14.6 | -20.54 | |||||
Tangible Book Value, 2 Yr. CAGR % | 77.54 | 73.16 | 34.25 | 13.07 | -30.06 | |||||
Common Equity, 2 Yr. CAGR % | 75.28 | 71.41 | 33.58 | 12.79 | -29.09 | |||||
Cash From Operations, 2 Yr. CAGR % | 149.47 | -24.58 | 2.83 | 48.97 | -24.21 | |||||
Capital Expenditures, 2 Yr. CAGR % | 83.64 | 32.56 | -23.38 | -19.98 | -26.11 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 59.94 | 537.66 | -28.06 | 63.7 | 123.06 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 64.42 | 1.4T | -27.29 | 63.68 | 122.41 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.55 | 0 | 41.42 | -22.54 | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 80.32 | 53.46 | 51.59 | -5.25 | -38.37 | |||||
Gross Profit, 3 Yr. CAGR % | 73.77 | 42.19 | 33.32 | -21.94 | 0.44 | |||||
EBITDA, 3 Yr. CAGR % | 89.59 | 44.97 | 32.05 | -39.6 | 22.83 | |||||
EBITA, 3 Yr. CAGR % | 90.78 | 44.79 | 31.84 | -41.89 | 25.17 | |||||
EBIT, 3 Yr. CAGR % | 90.7 | 44.78 | 31.91 | -41.91 | 25.47 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 91.6 | 47.14 | 34.71 | -41.74 | 25.06 | |||||
Net Income, 3 Yr. CAGR % | 91.6 | 47.14 | 34.71 | -41.74 | 25 | |||||
Normalized Net Income, 3 Yr. CAGR % | 91.26 | 45.99 | 33.14 | -42.85 | 26.29 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 91.6 | 47.14 | 34.71 | -41.7 | 25.1 | |||||
Accounts Receivable, 3 Yr. CAGR % | 86.72 | 66.86 | 59.85 | 8.14 | -18.49 | |||||
Inventory, 3 Yr. CAGR % | 60.56 | 47.79 | 38.18 | 44.36 | -14.55 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 32.62 | 33.25 | 28.97 | 14.72 | 7.8 | |||||
Total Assets, 3 Yr. CAGR % | 64.01 | 51.44 | 48.9 | 18.43 | -5.85 | |||||
Tangible Book Value, 3 Yr. CAGR % | 64.16 | 63.23 | 57.62 | 20.83 | -13.87 | |||||
Common Equity, 3 Yr. CAGR % | 61.64 | 61.56 | 56.32 | 20.42 | -13.22 | |||||
Cash From Operations, 3 Yr. CAGR % | 144.01 | 13.32 | 37.03 | -19.65 | 37.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | 59.09 | 36.37 | 11.1 | -21.62 | -24.75 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 63.6 | 51.58 | 149.1 | 53.95 | 23.67 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 65.69 | 53.34 | 347.71 | 52.88 | 25.16 | |||||
Dividend Per Share, 3 Yr. CAGR % | 6.27 | 0 | 33.89 | -20.63 | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 133.04 | 95.42 | 58.87 | 19.75 | -10.02 | |||||
Gross Profit, 5 Yr. CAGR % | 107.7 | 65.69 | 37.36 | 9.87 | 17.07 | |||||
EBITDA, 5 Yr. CAGR % | 185.07 | 74.65 | 39.45 | -1.71 | 32.2 | |||||
EBITA, 5 Yr. CAGR % | 248.71 | 76.78 | 39.71 | -3.88 | 33.61 | |||||
EBIT, 5 Yr. CAGR % | 303.77 | 77.53 | 39.87 | -3.99 | 33.77 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 215.76 | 77.14 | 40.93 | -3.13 | 34.89 | |||||
Net Income, 5 Yr. CAGR % | 215.76 | 77.14 | 40.93 | -3.13 | 34.85 | |||||
Normalized Net Income, 5 Yr. CAGR % | 218.42 | 76.61 | 40.03 | -4.46 | 35.14 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 216.94 | 77.14 | 40.94 | -3.09 | 34.92 | |||||
Accounts Receivable, 5 Yr. CAGR % | 112.07 | 96.67 | 68.76 | 29.68 | 11.01 | |||||
Inventory, 5 Yr. CAGR % | 134.37 | 66.45 | 38.17 | 54.99 | 8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 26.24 | 30.02 | 27.41 | 22.04 | 19.76 | |||||
Total Assets, 5 Yr. CAGR % | 61.8 | 56.06 | 49.13 | 35.46 | 15.83 | |||||
Tangible Book Value, 5 Yr. CAGR % | 49.85 | 54.43 | 51.47 | 40.94 | 13.88 | |||||
Common Equity, 5 Yr. CAGR % | 47.59 | 52.51 | 49.77 | 39.93 | 13.94 | |||||
Cash From Operations, 5 Yr. CAGR % | 148.4 | 57.75 | 72.7 | 26.42 | 8.12 | |||||
Capital Expenditures, 5 Yr. CAGR % | 44.37 | 44.48 | 18.77 | 10.18 | -5.62 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 70.78 | 114.49 | 17.78 | 56.32 | 138.34 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 71.19 | 116.61 | 19.18 | 57.39 | 238.42 | |||||
Dividend Per Share, 5 Yr. CAGR % | 126.57 | 30.91 | 19.14 | -9.71 | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















